WINTON GROUP Ltd Has $2 Million Holdings in LifeStance Health Group, Inc. $LFST

WINTON GROUP Ltd lifted its stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) by 522.3% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 186,589 shares of the company’s stock after acquiring an additional 156,607 shares during the period. WINTON GROUP Ltd’s holdings in LifeStance Health Group were worth $1,998,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Assetmark Inc. lifted its holdings in LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after purchasing an additional 1,367 shares during the last quarter. Allworth Financial LP grew its holdings in LifeStance Health Group by 7.7% during the second quarter. Allworth Financial LP now owns 26,532 shares of the company’s stock valued at $284,000 after purchasing an additional 1,889 shares during the last quarter. California State Teachers Retirement System grew its holdings in LifeStance Health Group by 1.6% during the fourth quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock valued at $885,000 after purchasing an additional 1,966 shares during the last quarter. Vident Advisory LLC raised its position in shares of LifeStance Health Group by 12.7% in the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after purchasing an additional 2,447 shares during the period. Finally, Xponance LLC raised its position in shares of LifeStance Health Group by 26.4% in the fourth quarter. Xponance LLC now owns 13,144 shares of the company’s stock valued at $93,000 after purchasing an additional 2,745 shares during the period. 85.50% of the stock is owned by institutional investors.

LifeStance Health Group Trading Down 0.2%

Shares of LifeStance Health Group stock opened at $12.97 on Friday. The company’s fifty day simple moving average is $11.67 and its 200-day simple moving average is $9.00. The company has a market cap of $4.96 billion, a price-to-earnings ratio of 99.78 and a beta of 1.22. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18. LifeStance Health Group, Inc. has a 1 year low of $4.77 and a 1 year high of $13.28.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The firm had revenue of $435.35 million during the quarter, compared to analysts’ expectations of $414.58 million. During the same period in the prior year, the company earned ($0.01) EPS. The business’s quarterly revenue was up 26.1% compared to the same quarter last year. As a group, sell-side analysts expect that LifeStance Health Group, Inc. will post 0.16 EPS for the current year.

Key LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Barclays raised its price target for LifeStance Health Group from $13 to $15 and maintained an “overweight” rating, implying further upside from the stock’s recent level. Barclays price target report
• Positive Sentiment: Zacks highlighted LFST as a strong momentum candidate, reinforcing investor interest after the shares’ substantial appreciation over the past year. Zacks momentum stock analysis
• Positive Sentiment: The company’s latest quarterly results showed strong operating momentum: revenue increased 26.1% year over year to $435.4 million, while adjusted earnings of $0.06 per share exceeded expectations of $0.03. The company is also projected to remain profitable for the full year.
• Neutral Sentiment: LifeStance announced a secondary offering alongside a share repurchase program. The repurchase could help absorb some of the shares being offered and support the stock, although the overall effect depends on the offering size and terms. LifeStance secondary offering and share repurchase announcement
• Neutral Sentiment: Brokerages collectively rate LFST a “Moderate Buy,” suggesting generally favorable expectations but not unanimous conviction.
• Negative Sentiment: The secondary offering may create additional share supply and weigh on the stock in the near term, particularly after its sharp run-up. The stock also trades at a high valuation—roughly 100 times earnings—leaving it sensitive to changes in growth expectations.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on LFST. JPMorgan Chase & Co. boosted their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. BTIG Research lifted their target price on shares of LifeStance Health Group from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, August 19th. Barclays boosted their target price on shares of LifeStance Health Group from $13.00 to $15.00 and gave the stock an “overweight” rating in a research report on Thursday. Wall Street Zen cut shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. Finally, Canaccord Genuity Group raised their price target on LifeStance Health Group from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, LifeStance Health Group has a consensus rating of “Moderate Buy” and a consensus price target of $12.88.

Insider Transactions at LifeStance Health Group

In other news, COO Lisa Miller sold 47,912 shares of LifeStance Health Group stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the sale, the chief operating officer owned 281,289 shares of the company’s stock, valued at approximately $3,051,985.65. This trade represents a 14.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Bessler sold 894,337 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $10.13, for a total value of $9,059,633.81. Following the sale, the director owned 539,763 shares in the company, valued at approximately $5,467,799.19. This represents a 62.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 14,671,917 shares of company stock worth $155,493,415 over the last 90 days. Insiders own 3.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc is a behavioral health care company that provides outpatient mental health services through in-person and virtual appointments. Its platform connects patients with psychiatrists, psychologists, psychiatric nurse practitioners, therapists and other licensed clinicians.

The company offers services that may include psychotherapy, psychiatric evaluations, medication management and treatment for conditions such as anxiety, depression, attention-deficit/hyperactivity disorder and other behavioral health needs.